BACKGROUND AND AIMS: @entity29 ( @entity29 ) commonly affects @entity1 during their reproductive years, leading to concerns regarding pregnancy outcomes and therapeutic safety. The aim of this study was to assess the risks associated with anti- @entity5 @entity39 factor a (anti- @entity310 ) therapy for pregnancy outcomes, including rates of @entity154 , based on published studies. METHODS: Published studies were screened from on-line databases and international meeting abstracts. A meta-analysis was performed for adverse pregnancy outcomes (APOs), @entity154 ( @entity154 ), preterm birth (PTB) and low birth weight (LBW). The prevalence of @entity154 was compared with whole-population pooled registry data. RESULTS: In @entity1 exposed to anti- @entity310 the pooled odds ratio for APOs was 1.14 (95% confidence interval [CI] 0.73-1.78; p = 0.55) compared with disease-matched controls. The pooled odds ratios for @entity154 , PTB and LBW were 0.89 (0.37-2.13; p = 0.79), 1.21 (0.74-2.00; p = 0.45) and 1.36 (0.77-2.38; p = 0.29) respectively. The rate of @entity154 in @entity310 -exposed @entity1 was not statistically different from that in population-wide registries (difference 0.4%, 95% CI -2.0 to +2.7). CONCLUSIONS: Anti- @entity310 therapy does not increase the risk of APOs, @entity154 , PTB or LBW compared with disease-matched controls. Furthermore, the risk of @entity154 is not increased when published prevalence data are compared with data for the general population. These findings may offer some reassurance for @entity1 and physicians regarding the safety profile of anti- @entity310 during pregnancy in @entity29 .

XXXX Factor a Therapies and Inflammatory Bowel Disease Pregnancy Outcomes: A Meta-analysis.

@entity1 :: ('9606', 'Species') :: ['women'] @entity154 :: ('MESH:D000013', 'Disease') :: ['congenital abnormality', 'congenital abnormalities', 'CAs'] @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis'] @entity310 :: ('7124', 'Gene') :: ['TNFa'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour'] @entity29 :: ('MESH:D015212', 'Disease') :: ['Inflammatory bowel disease', 'IBD']
@entity5 :: (MESH:D009369,Disease) :: ['Anti-Tumour Necrosis']
